This site is intended for healthcare professionals

GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist.

Read time: 1 mins
Published:16th Apr 2021
GlaxoSmithKline plc announced, following a recommendation by the Independent Data Monitoring Committee, that it has taken the decision to stop enrolling patients in the phase II INDUCE-3 trial , including discontinuing treatment with feladilimab. The INDUCE-3 study is investigating feladilimab in combination with pembrolizumab versus placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma. GSK has also made the decision to stop the INDUCE-4 phase II trial, a study investigating feladilimab versus placebo in combination with pembrolizumab and chemotherapy.
Condition: Head & Neck Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.